Free Trial

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific logo
$90.30 -0.15 (-0.17%)
(As of 11/19/2024 ET)

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
20

Based on 23 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 3 have given a hold rating, 19 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$93.39
3.42% Upside
According to the 23 analysts' twelve-month price targets for Boston Scientific, the average price target is $93.39. The highest price target for BSX is $110.00, while the lowest price target for BSX is $68.00. The average price target represents a forecasted upside of 3.42% from the current price of $90.30.
Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

Sign Up

BSX Analyst Ratings Over Time

TypeCurrent Forecast
11/21/23 to 11/20/24
1 Month Ago
10/22/23 to 10/21/24
3 Months Ago
8/23/23 to 8/22/24
1 Year Ago
11/21/22 to 11/21/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
19 Buy rating(s)
17 Buy rating(s)
18 Buy rating(s)
14 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$93.39$90.24$85.24$60.55
Forecasted Upside3.42% Upside2.49% Upside7.11% Upside9.45% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Boston Scientific Stock vs. The Competition

TypeBoston ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside3.42% Upside27,981.05% Upside9.99% Upside
News Sentiment Rating
Positive News

See Recent BSX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/18/2024Needham & Company LLC
2 of 5 stars
M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
10/24/2024Sanford C. Bernstein
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$92.00 ➝ $100.00+16.41%
10/24/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$92.00 ➝ $100.00+16.69%
10/24/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$95.00 ➝ $98.00+13.49%
10/24/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$87.00 ➝ $98.00+13.70%
10/24/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$92.00 ➝ $98.00+11.74%
10/24/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $110.00+25.79%
10/22/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $100.00+13.39%
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$86.00 ➝ $100.00+12.55%
10/21/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$88.00 ➝ $98.00+11.28%
10/18/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$85.00 ➝ $100.00+14.17%
10/14/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$84.00 ➝ $93.00+6.72%
10/14/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $100.00+14.68%
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$82.00 ➝ $90.00+7.80%
9/4/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$91.00 ➝ $94.00+15.85%
8/22/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$78.00 ➝ $86.00+8.08%
7/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$73.00 ➝ $78.00+2.63%
7/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$82.00 ➝ $85.00+8.83%
7/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$90.00 ➝ $91.00+17.03%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+20.05%
5/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$80.00 ➝ $95.00+26.51%
4/25/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$74.00 ➝ $90.00+22.97%
2/1/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$58.00 ➝ $68.00+5.44%
7/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$58.00 ➝ $62.00+16.43%
6/30/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingInitiates
6/30/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$64.00+20.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:11 AM ET.


Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, November 3, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Co. has shown consistent revenue growth, with a 14.5% increase in revenue year-over-year.
  • Analysts forecast a positive earnings per share of 2.4 for the current fiscal year, indicating profitability.
  • Recent institutional trading activity has seen large investors increasing their stakes in the company, signaling confidence in its future performance.
  • Multiple Wall Street analysts have given Boston Scientific Co. a "buy" or "strong-buy" rating, with price targets well above the current stock price.
  • The stock price of Boston Scientific Co. has been trading up, reaching $83.24, showing positive momentum in the market.

Boston Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Despite positive analyst ratings, there is always a level of risk associated with investing in the stock market, including potential market volatility.
  • The company operates in the healthcare sector, which can be subject to regulatory changes and unpredictable market conditions.
  • Insider selling activity has been observed, with company executives selling shares, which could be perceived as a lack of confidence in the company's future prospects.
  • The stock has a relatively high P/E ratio of 69.88, which may indicate that the stock is currently overvalued compared to its earnings.
  • While the stock has shown positive growth, past performance is not indicative of future results, and there are no guarantees of continued success.

BSX Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $93.39, with a high forecast of $110.00 and a low forecast of $68.00.

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 3.42% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 1 downgrade by analysts.

Analysts like Boston Scientific more than other "medical" companies. The consensus rating score for Boston Scientific is 2.91 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BSX compares to other companies.


This page (NYSE:BSX) was last updated on 11/20/2024 by MarketBeat.com Staff
From Our Partners